Red Blood Cell Membrane Spontaneously Coated Nanoprodrug Based on Phosphatidylserine for Antiatherosclerosis Applications

Atherosclerosis (AS) is characterized by the accumulation of lipids within the walls of coronary arteries, leading to arterial narrowing and hardening. It serves as the primary etiology and pathological basis for cardiovascular diseases affecting the heart and brain. However, conventional pharmacoth...

Full description

Saved in:
Bibliographic Details
Published in:ACS applied materials & interfaces 2024-09, Vol.16 (35), p.46578-46589
Main Authors: Cao, Yu, Han, ZhiQiang, Zhu, Li, He, Zhigui, Mou, Nianlian, Duan, Xinmei, Chen, Qiao, Qin, Xian, Zhang, Kun, Qu, Kai, Zhong, Yuan, Wu, Wei
Format: Article
Language:English
Subjects:
atherosclerosis
biocompatibility
biomimetics
brain
disease progression
drug therapy
drugs
erythrocyte membrane
etiology
Functional Nanostructured Materials (including low-D carbon)
heart
nanomedicine
phagocytes
phosphatidylserines
polypeptides
toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atherosclerosis (AS) is characterized by the accumulation of lipids within the walls of coronary arteries, leading to arterial narrowing and hardening. It serves as the primary etiology and pathological basis for cardiovascular diseases affecting the heart and brain. However, conventional pharmacotherapy is constrained by inadequate drug delivery and pronounced toxic side effects. Moreover, the inefficacy of nanomedicine delivery systems in controlling disease progression may be attributed to nonspecific clearance by the mononuclear phagocyte system. Thus, a biomimetic platform spontaneously enveloped by red blood cell membrane is exploited for anti-atherosclerosis applications, offering favorable biocompatibility. The CLIKKPF polypeptide is introduced to develop red blood cell membrane spontaneously encapsulated nanotherapeutics only through simple coincubation. Given the functional modifications, RBC@P-LVTNPs is beneficial to facilitate the target drug delivery to the atherosclerotic lesion, responding precisely to the pathological ROS accumulation, thereby accelerating the on-demand drug release. Both in vivo and in vitro results also confirm the significant therapeutic efficacy and favorable biocompatibility of the biomimetic nanomedicine delivery system, thus providing a promising candidate for nanotherapeutics against AS.
ISSN:1944-8244
1944-8252
1944-8252
DOI:10.1021/acsami.4c07720